Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 939230

PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early- stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial

Chia, S.K.L.; Martin, M.; Holmes, F.A.; Ejlertsen, B.; Delaloge, S.; Moy, B.; Iwata, H.; von Minckwitz, G.; Mansi, J.; Barrios, C.H. et al.
PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early- stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial // Cancer Research / Van Dang, Chi (ur.).
Philadelphia (PA): American Association for Cancer Research, 2018. str. PD3-12 doi:10.1158/1538-7445.SABCS17-PD3-12 (poster, međunarodna recenzija, sažetak, stručni)

CROSBI ID: 939230 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early- stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial

Autori
Chia, S.K.L. ; Martin, M. ; Holmes, F.A. ; Ejlertsen, B. ; Delaloge, S. ; Moy, B. ; Iwata, H. ; von Minckwitz, G. ; Mansi, J. ; Barrios, C.H. ; Gnant, M. ; Tomašević, Z. ; Denduluri, N. ; Šeparović, Robert ; Kim, Jakobsen, E.H. ; Harvey, V. ; Robert, N. ; Smith, J.I.I. ; Harker, G. ; Lalani, A.S. ; Zhang, B. ; Eli, L.D. ; Chan, A.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Cancer Research / Van Dang, Chi - Philadelphia (PA) : American Association for Cancer Research, 2018, PD3-12

Skup
San Antonio Breast Cancer Symposium (SABCS) 2018

Mjesto i datum
San Antonio (TX), Sjedinjene Američke Države, 04.12.2018. - 08.12.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
neratinib ; trastuzumab ; ExteNET studija ; rani HER2 pozitivni karcinom dojke
(neratinib ; trastuzumab ; ExteNET trial ; early HER2 positive breast cancer)

Sažetak
One year of neratinib treatment after trastuzumab- based adjuvant therapy significantly improves iDFS after 5 years in patients with early-stage HER2+ breast cancer. From this modest-sized exploratory cohort, it appears that PIK3CA may be a biomarker for differential sensitivity to neratinib after 1 year of trastuzumab in the adjuvant setting.These exploratory results should be validated in a larger subset.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA

Ustanove:
Klinika za tumore

Profili:

Avatar Url Tong Zhang (autor)

Avatar Url Robert Šeparović (autor)

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Chia, S.K.L.; Martin, M.; Holmes, F.A.; Ejlertsen, B.; Delaloge, S.; Moy, B.; Iwata, H.; von Minckwitz, G.; Mansi, J.; Barrios, C.H. et al.
PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early- stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial // Cancer Research / Van Dang, Chi (ur.).
Philadelphia (PA): American Association for Cancer Research, 2018. str. PD3-12 doi:10.1158/1538-7445.SABCS17-PD3-12 (poster, međunarodna recenzija, sažetak, stručni)
Chia, S., Martin, M., Holmes, F., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Mansi, J. & Barrios, C. (2018) PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early- stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial. U: Van Dang, C. (ur.)Cancer Research doi:10.1158/1538-7445.SABCS17-PD3-12.
@article{article, author = {Chia, S.K.L. and Martin, M. and Holmes, F.A. and Ejlertsen, B. and Delaloge, S. and Moy, B. and Iwata, H. and von Minckwitz, G. and Mansi, J. and Barrios, C.H. and Gnant, M. and Toma\v{s}evic\', Z. and Denduluri, N. and \v{S}eparovic\', Robert and Harvey, V. and Robert, N. and Smith, J.I.I. and Harker, G. and Lalani, A.S. and Zhang, B. and Eli, L.D. and Chan, A.}, editor = {Van Dang, C.}, year = {2018}, pages = {PD3-12-PD3-12}, DOI = {10.1158/1538-7445.SABCS17-PD3-12}, keywords = {neratinib, trastuzumab, ExteNET studija, rani HER2 pozitivni karcinom dojke}, doi = {10.1158/1538-7445.SABCS17-PD3-12}, title = {PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early- stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial}, keyword = {neratinib, trastuzumab, ExteNET studija, rani HER2 pozitivni karcinom dojke}, publisher = {American Association for Cancer Research}, publisherplace = {San Antonio (TX), Sjedinjene Ameri\v{c}ke Dr\v{z}ave} }
@article{article, author = {Chia, S.K.L. and Martin, M. and Holmes, F.A. and Ejlertsen, B. and Delaloge, S. and Moy, B. and Iwata, H. and von Minckwitz, G. and Mansi, J. and Barrios, C.H. and Gnant, M. and Toma\v{s}evic\', Z. and Denduluri, N. and \v{S}eparovic\', Robert and Harvey, V. and Robert, N. and Smith, J.I.I. and Harker, G. and Lalani, A.S. and Zhang, B. and Eli, L.D. and Chan, A.}, editor = {Van Dang, C.}, year = {2018}, pages = {PD3-12-PD3-12}, DOI = {10.1158/1538-7445.SABCS17-PD3-12}, keywords = {neratinib, trastuzumab, ExteNET trial, early HER2 positive breast cancer}, doi = {10.1158/1538-7445.SABCS17-PD3-12}, title = {PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early- stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial}, keyword = {neratinib, trastuzumab, ExteNET trial, early HER2 positive breast cancer}, publisher = {American Association for Cancer Research}, publisherplace = {San Antonio (TX), Sjedinjene Ameri\v{c}ke Dr\v{z}ave} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.